Tazverik Tablet, Film Coated
NDC Package 72607-100-00

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Tazverik (tazemetostat) tablets is tAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This formulation utilizes a tablet, film coated delivery system. Marketed by Epizyme, Inc., this product is identified by NDC 72607-100 and is authorized under FDA application NDA211723.

Identification & Billing

NDC Package Code
72607-100-00
Package Description
240 TABLET, FILM COATED in 1 BOTTLE
Product Code
72607-100
11-Digit Billing Format
72607010000
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tazverik
Non-Proprietary Name
Tazemetostat
Substance Name
Tazemetostat Hydrobromide
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
TAZEMETOSTAT HYDROBROMIDE 200 mg/1
Pharmacologic Class
Usage Information
TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Regulatory & Marketing

Labeler Name
Epizyme, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA211723
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-23-2020
End Marketing Date
04-30-2029
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72607-100-00 identifies a specific commercial package of 240 tablet, film coated in 1 bottle of Tazverik, a human prescription drug labeled by Epizyme, Inc.. This tablet, film coated is formulated for oral use and contains tazemetostat hydrobromide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Epizyme, Inc. on January 23, 2020.

How is this Epizyme, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72607010000. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72607-100-00
11-Digit CMS (5-4-2)
72607-0100-00

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.